NJ A 4550
in committeeRequires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.
New Jersey · 222 · lower
Quick answers
Did NJ A 4550 pass?
Not yet. NJ A 4550 is in committee as of 2026-03-10 and has not come to a final vote. Latest recorded action (2026-03-10): Introduced, Referred to Assembly Financial Institutions and Insurance Committee
What is NJ A 4550 about?
NJ A 4550 is a bill in the 222 titled “Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.”.
Who sponsors NJ A 4550?
Murphy, Carol A. is the primary sponsor of NJ A 4550.
- Introduced
- 2026-03-10
- Latest action
- 2026-03-10 — Introduced, Referred to Assembly Financial Institutions and Insurance Committee
- Bill type
- bill
- Last updated
- —
Sponsors
- Murphy, Carol A.primary
Committees
Not provided by source.
Action timeline
2026-03-10
Introduced, Referred to Assembly Financial Institutions and Insurance Committee
introduction,referral-committee
Versions
- IntroducedCompare
Documents
Votes
Not provided by source.
Related bills
No related bills recorded for this bill.
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:27:43.923511Z
Inspect retained evidence for changes recorded after evidence tracking began:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NJ&identifier=A 4550. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.